Positive CHMP opinion for BioMarin's Vimizim for Morquio A syndrome

BioMarin Pharmaceutical (Nasdaq: BMRN) says that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for its Vimizim (elosulfase alfa) for the treatment of Morquio A syndrome, also called Mucopolysaccharidosis Type IVA (MPS IVA).

The CHMP's recommendation is now referred to the European Commission. If approved by the EC, BioMarin would receive marketing authorization for Vimizim in all European Union member states. The EC is expected to render a final decision in the second quarter of 2014.

Follows FDA approval